Cargando…

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers

Affibody-based imaging of HER3 is a promising approach for patient stratification. We investigated the influence of a hydrophilic HEHEHE-tag ((HE)(3)-tag) and two different gallium-68/chelator-complexes on the biodistribution of Z(08698) with the aim to improve the tracer for PET imaging. Affibody m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahlsson Leitao, Charles, Rinne, Sara S., Mitran, Bogdan, Vorobyeva, Anzhelika, Andersson, Ken G., Tolmachev, Vladimir, Ståhl, Stefan, Löfblom, John, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429182/ https://www.ncbi.nlm.nih.gov/pubmed/30832342 http://dx.doi.org/10.3390/ijms20051080

Ejemplares similares

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
por: Rinne, Sara S., et al.
Publicado: (2019)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
por: Rinne, Sara S., et al.
Publicado: (2019)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2022)

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
por: Garousi, Javad, et al.
Publicado: (2019)

Cyclic versus Noncyclic Chelating Scaffold for (89)Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
por: Summer, Dominik, et al.
Publicado: (2017)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
por: Dahlsson Leitao, Charles, et al.
Publicado: (2020)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Preclinical Evaluation of [(68)Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with (99m)Tc using a peptide-based cysteine-containing chelator
por: Andersson, Ken G., et al.
Publicado: (2016)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

Preclinical Evaluation of a New Format of (68)Ga- and (111)In-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
por: Liu, Yongsheng, et al.
Publicado: (2022)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Imaging of CAIX-expressing xenografts in vivo using (99m)Tc-HEHEHE-ZCAIX:1 Affibody molecule
por: HONARVAR, HADIS, et al.
Publicado: (2014)

Influence of Macrocyclic Chelators on the Targeting Properties of (68)Ga-Labeled Synthetic Affibody Molecules: Comparison with (111)In-Labeled Counterparts
por: Strand, Joanna, et al.
Publicado: (2013)

Optimal composition and position of histidine-containing tags improves biodistribution of (99m)Tc-labeled DARPin G3
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
por: Bass, Tarek Z., et al.
Publicado: (2017)

PET imaging of epidermal growth factor receptor expression in tumours using (89)Zr-labelled ZEGFR:2377 affibody molecules
por: GAROUSI, JAVAD, et al.
Publicado: (2016)

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
por: Mitran, Bogdan, et al.
Publicado: (2018)

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule
por: Garousi, Javad, et al.
Publicado: (2017)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69
por: Persson, Jonas, et al.
Publicado: (2021)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches
por: Güler, Rezan, et al.
Publicado: (2020)

Comparative Evaluation of Novel (177)Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
por: Tano, Hanna, et al.
Publicado: (2021)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope (66)Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
por: Garousi, Javad, et al.
Publicado: (2020)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
por: Yin, Wen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivatkpcrcq91d3q5f38nvsegdt